Recce Pharmaceuticals Boosts Anti-Infective Production

Recce Pharmaceuticals Limited (ASX: RCE), based in Sydney, has significantly increased its production capacity, now manufacturing 5,000 doses weekly of its anti-infective RECCE® 327 (R327). This scale-up meets Good Manufacturing Practices (GMP) standards and supports ongoing clinical trials, including a forthcoming Phase III study for Diabetic Foot Ulcer Infections.

The company adapted its operations by utilizing an external GMP-certified facility, enhancing its fill and finish processes. This development is critical for maintaining supply for clinical demands and advances Recce closer to an Investigational New Drug (IND) submission, reinforcing its role in tackling antimicrobial resistance.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com